News | Radiopharmaceuticals and Tracers | March 26, 2021

Shine Medical Announces its Isotope Production Facility is Weathertight

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status

Shine executives are joined by the company’s construction managers and partners at its medical isotope production facility. The group was commemorating the facility’s achievement of weathertight status. Image courtesy of Shine Medical Technologies

March 26, 2021 — Shine Medical Technologies LLC announced that construction of the exterior structure of its first-of-a-kind medical isotope production facility is complete and the building is weathertight, a major milestone with significance for Shine, the medical isotope industry and patients around the world.

Reaching the weathertight milestone moves Shine one step closer to providing a flexible, reliable supply of molybdenum-99 (Mo-99) and other neutron-produced isotopes to customers, physicians and patients. It means that the 46,000-square-foot building is now sealed against the elements and the installation of Shine’s high-tech process equipment can begin. The production facility has been built to withstand tornados, airplane crashes and other catastrophic events, and is expected to be a major producer of medicine for decades to come.

“This milestone marks a leveling-up for our team, which includes our internal staff, but also all those who helped do the work in the field,” said Greg Piefer, founder and CEO of Shine. “We’ve now demonstrated we can execute against a challenging first-of-a-kind nuclear build and do so within schedule and budget contingencies— all during a global pandemic. I am incredibly proud of the grit, dedication and skill of all those involved as we worked together to tackle complicated problems in challenging conditions. The results of the team’s hard work say a lot about their extraordinary dedication, talent and commitment to improving the lives of patients everywhere.”

The plant is expected to be the largest medical isotope production facility in the world by capacity. Shine is installing the specialized process equipment in the facility during the next year, and expects to begin producing Mo-99 in late 2022.

“Baker Concrete Construction is proud to be one of Shine’s partner in the construction of this important facility and we’re excited to have been given the opportunity to play a key role in getting the project to weathertight,” said Matt Jorn, project executive of Baker. “We understand what this plant means, not just to Shine, but to patients around the globe. This commitment makes our involvement in the facility’s construction even more meaningful. Doing our part to bring the facility to weathertight is something that the entire Baker team takes great pride in.”

In addition to Baker, Shine’s construction partners include J.H. Findorff & Son Inc., Sargent & Lundy LLC, Lycon Inc., and Westphal & Co.

For more information: www.shinemed.com

Related Shine Isotope Production News:

FDA Approves Additional Molybdenum-99 (Mo-99) Filling Lines at NorthStar Medical Radioisotopes

Shine Medical Approved to Build Domestic Molybdenum-99 Production Facility

BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method

Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility

World Record for Strongest Nuclear Fusion Reaction in a Steady-State System Achieved by Phoenix and Shine

Related Content

IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, and SCK CEN (Belgian Nuclear Research Center) announced a strategic R&D partnership to enable the production of Actinimum-225 (225Ac), a novel radioisotope which has significant potential in the treatment of cancer.
News | Radiation Oncology | September 17, 2021
September 17, 2021 — IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology, a
Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
With a wealth of landmark studies in Breast, Cervical, Melanoma, Prostate, Colorectal, Oesophagus, Endocrine and Lung cancer, the ESMO Congress 2021 is a clear demonstration that oncology research has once again gathered momentum after being temporarily stopped in its tracks by the outbreak of the virus

Getty Images

News | Radiation Oncology | September 13, 2021
September 13, 2021 — At the opening press conference of the ...
Comment letters on the 2022 physician fee schedule and Radiation Oncology Model urge CMS to scale back extreme cuts that jeopardize access to life-saving cancer treatments

Getty Images

News | ASTRO | September 09, 2021
September 9, 2021 — The American Society for Radiation Oncology (AS...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
An artificial intelligence (AI) program can spot signs of lung cancer on computed tomography (CT) scans a year before they can be diagnosed with existing methods, according to research presented at the European Respiratory Society International Congress.

Diagram showing details of the lung screening experiment. Image courtesy of the European Respiratory Society/Benoit Audelan

News | Artificial Intelligence | September 08, 2021
September 8, 2021 — An artificial intell...